Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: High low-density lipoprotein-cholesterol (LDL-C) is a public health issue contributing to ischemic heart disease (IHD) and stroke. Method: In this ecological study, we collected summary exposure values (SEVs), deaths, disability-adjusted life of years (DALYs), and Social Demographic Index (SDI) of high LDL-C from 1990 to 2019 using the query tool from the Global Burden of Disease (GBD) Collaborative Network. Outcomes include SEVs, deaths, and DALYs attributable to high LDL-C stratified by sex, age, region, SDI, countries, and territories. Estimated annual percentage changes (EAPCs) were applied to estimate annual trends of changes in these outcomes. We applied the weighted segmented regression with break-point estimation to detect the linear piecewise relationship between SDI and high LDL-C disease burden. Results: Globally, 3.00 million (95% uncertainty interval [UI], 2.35–3.76 million) people in 1990 and 4.40 million (95% UI, 3.30–5.65 million) people died from high LDL-C in 2019. The absolute annual burden from deaths and DALYs attributed to high LDL-C increased by 46% (95% UI, 35–56%) and 41% (95% UI, 31–50%) from 1990 to 2019. The age-standardized SEV, death, and DALY was decreased by 9% (95% UI, −11 to −8%), 37% (95% UI, −41−33%), and 32% (95% UI, −37 to −28%), respectively, during the study period. There was a negative association between SDI and high LDL-C-related age-standardized death and DALY rates when SDI surpassed 0.71 and 0.71, respectively. Conclusion: Although the overall age-standardized burden of high LDL-C is controlled in the past 30 years, it remains increasing in moderate SDI countries, and decreasing trends are disappearing in high SDI countries. New challenges require new actions stratified by countries with different SDI levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
Self-citationHeart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Self-citationGuidelines for accurate and transparent health estimates reporting: the GATHER statement
Stevens, G. A., Alkema, L., Black, R. E., Boerma, J. T., Collins, G. S., Ezzati, M., Grove, J. T., Hogan, D. R., Hogan, M. C., Horton, R., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002056 · Cited by 424
Interventions to improve adherence to lipid-lowering medication
van Driel, M. L., Morledge, M. D., Ulep, R., Shaffer, J. P., Davies, P., & Deichmann, R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub4 · Cited by 333
Khan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069116 · Cited by 151
Self-citation
Research works printed but not linked: 29
- 2021, 17 Goals to Transform Our World.
- Reddy, 2016, Global burden of disease study 2015 provides GPS for global health 2030., Lancet., 388, 1448, 10.1016/S0140-6736(16)31743-3 · DOI · Paper page
- Nelson, 2013, Hyperlipidemia as a risk factor for cardiovascular disease., Prim Care., 40, 195, 10.1016/j.pop.2012.11.003 · DOI · Paper page
- Zeng, 2021, Low-density lipoprotein cholesterol and novel lipid parameters in predicting clinical outcomes in Chinese statin-naïve patients after coronary stent implantation., Front Cardiovasc Med., 8, 10.3389/fcvm.2021.638663 · DOI
- Wenger, 2010, Cardiovascular Disability: Updating the Social Security Listings.
- Butowski, 1998, Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the UK lipid clinics programme., Eur Heart J., 19, 1328, 10.1053/euhj.1998.1044 · DOI
- 2020, Global Burden of Disease Study 2019 (GBD 2019) Results.
- Murray, 2020, Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019., Lancet., 396, 1223, 10.1016/S0140-6736(20)30752-2 · DOI · Paper page
- Pencina, 2020, The expected 30-year benefits of early versus delayed primary prevention of cardiovascular disease by lipid lowering., Circulation., 142, 827, 10.1161/CIRCULATIONAHA.120.045851 · DOI · Paper page
- Olejaz, 2012, Denmark health system review., Health Syst Transit., 14, i
- Forde, 2016, Primary Care Review of Denmark., 6
- Clarfield, 2017, Health and health care in Israel: an introduction., Lancet., 389, 2503, 10.1016/S0140-6736(17)30636-0 · DOI · Paper page
- 2012, OECD Health Care Quality Review: Korea.
- 2020, Ageing.
- Riahi, 2001, Use of lipid-lowering drugs during 1991–98 in Northern Jutland, Denmark., Br J Clin Pharmacol., 52, 307, 10.1046/j.0306-5251.2001.01439.x · DOI
- Walley, 2005, Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003., Br J Clin Pharmacol., 60, 543, 10.1111/j.1365-2125.2005.02478.x · DOI · Paper page
- Gu, 2014, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012., NCHS Data Brief., 177, 1
- Du, 2019, Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis., Heart., 105, 1149, 10.1136/heartjnl-2019-314763 · DOI
- Hao, 2022, PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations., BMJ., 377, 10.1136/bmj-2021-069066 · DOI · Paper page
- Wang, 2022, Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies., BMJ Med., 1, 10.1136/bmjmed-2022-000134 · DOI · Paper page
- Li, 2022, Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis., Heart., 10.1136/heartjnl-2021-320556 · DOI
- Farrington, 2018, Prevention and Control of Noncommunicable Diseases in Uzbekistan.
- Wong, 2018, Priority setting for health service coverage decisions supported by public spending: experience from the Philippines., Health Syst Reform., 4, 19, 10.1080/23288604.2017.1368432 · DOI
- Azizi, 2009, Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II., Trials., 10, 10.1186/1745-6215-10-5 · DOI · Paper page
- Sdringola, 2003, Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease., J Am Coll Cardiol., 41, 263, 10.1016/s0735-1097(02)02693-1 · DOI
- 2018, The Astana declaration: the future of primary health care?, Lancet., 392
- 2020, Hearts: Technical Package for Cardiovascular Disease Management in Primary Health Care.
- Mendis, 2011, Global Atlas on Cardiovascular Disease Prevention and Control.
- Schröders, 2017, How is Indonesia coping with its epidemic of chronic noncommunicable diseases? A systematic review with meta-analysis., PLoS One., 12, 10.1371/journal.pone.0179186 · DOI
Metadata
- Authors
- Du, H., Shi, Q., Song, P., Pan, X.-F., Yang, X., Chen, L., He, Y., Zong, G., Zhu, Y., Su, B., & Li, S.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2022-06-09
- Volume
- 9
- ISSN
- 2297-055X
- Cited by
- 51
- References
- 7
- Funders
- West China Hospital, Sichuan University (grants ZYGD18022 and 20HXFH011 from the 1.3.5 Project for Disciplines of Excellence)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019. https://app.cochat.ai/papers/10.3389/fcvm.2022.903126
- The paper
- Du, H., Shi, Q., Song, P., Pan, X.-F., Yang, X., Chen, L., He, Y., Zong, G., Zhu, Y., Su, B., & Li, S. (2022). Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2022.903126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.